A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension

被引:13
作者
Fristrom, B
Nilsson, SEG
机构
[1] Department of Ophthalmology, University of Linköping, Linköping
关键词
D O I
10.1136/bjo.81.10.867
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Aim-To compare the intraocular pressure (IOP) reducing effect of latanoprost 0.005% and 0.001%. Methods-Twenty four patients with glaucoma or ocular hypertension were randomised into two groups. Twelve patients (group 1) were given latanoprost 0.005% once daily for 4 weeks and then latanoprost 0.001% once daily for the following 4 weeks. Twelve patients (group 2) were given latanoprost 0.001% once daily for 4 weeks and then latanoprost 0.005% for the following 4 weeks. Results-There was a significant IOP reduction from baseline in both groups on day 28 as well as on day 56. When the results from both groups were used for calculations, the mean IOP reduction from baseline after 4 weeks of treatment with latanoprost 0.005% (day 28 or 56) was 9.6 (SD 3.3) mm Hg (35.0%). After 4 weeks of treatment with latanoprost 0.001%, the IOP reduction (day 28 or 56) was 7.6 (3.4) mm Hg (27.7%). The difference in IOP reduction between the two concentrations was 2.0 (2.3) mm Hg (p<0.001). Conclusions-Latanoprost 0.005% was more effective than latanoprost 0.001% in reducing IOP. Even the lower concentration was surprisingly effective, and potentially may be of importance for use in clinical practice. Furthermore, it is at present unknown whether the increase in iris pigmentation seen in certain patients treated with latanoprost 0.005% is dose dependent and might be less pronounced with latanoprost 0.001%. Long term studies with a larger number of patients are required in order to answer this question.
引用
收藏
页码:867 / 870
页数:4
相关论文
共 15 条
[11]  
RACZ P, 1993, ARCH OPHTHALMOL-CHIC, V111, P1351
[12]  
TORIS CB, 1993, OPHTHALMOLOGY, V100, P1297
[13]   PHXA34 - A PROSTAGLANDIN-F2-ALPHA ANALOG - EFFECT ON INTRAOCULAR-PRESSURE IN PATIENTS WITH OCULAR HYPERTENSION [J].
VILLUMSEN, J ;
ALM, A .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1992, 76 (04) :214-217
[14]   A six-month, randomized, double masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension [J].
Watson, P ;
Stjernschantz, J ;
Beck, L ;
Blackmore, M ;
Coakes, R ;
Reynolds, P ;
Davey, C ;
HickmanCasey, J ;
Elkington, A ;
Luff, A ;
Green, F ;
Valenzuela, F ;
Longstaff, S ;
Currie, Z ;
Mills, B ;
Chatterjee, A ;
Murray, S ;
Nagasubramanian, S ;
Potts, M ;
Spencer, I ;
Roxburgh, S ;
Sanders, R ;
Bailey, M ;
Vernon, S ;
Sloper, M ;
Wishart, P ;
Birch, M .
OPHTHALMOLOGY, 1996, 103 (01) :126-137
[15]   THE EFFECTS ON AQUEOUS DYNAMICS OF PHXA41, A NEW PROSTAGLANDIN-F2-ALPHA ANALOG, AFTER TOPICAL APPLICATION IN NORMAL AND OCULAR HYPERTENSIVE HUMAN EYES [J].
ZIAI, N ;
DOLAN, JW ;
KACERE, RD ;
BRUBAKER, RF .
ARCHIVES OF OPHTHALMOLOGY, 1993, 111 (10) :1351-1358